You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Recombinant E-NTPDase for shock

    SBC: Purine Pharmaceuticals Inc.            Topic: 300

    SUMMARYInflammation after ischemia and reperfusion injury secondary to hemorrhagic shock is responsible for significant mortality and morbidity in the United States. Available intravenous fluids administered at the incident scene to treat hypovolemic shock do not completely prevent ischemia and reperfusion injury. Re-initiation of blood flow causes activation of several inflammatory mediators, suc ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Time-resolved laser speckle contrast imaging of resting-state functional connectivity in neonatal brain

    SBC: BIOPTICS TECHNOLOGY LLC            Topic: 103

    ABSTRACT Continuous monitoring of neonatal brain development is crucial for effective management of brain injury and associated complications, thus reducing healthcare burden and costs. One rapidly developing method for early characterization of abnormal brain development is to map resting-state functional connectivity (rs-FC) across distinct regions of the brain. However, currently available neur ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a novel broad spectrum antifungal therapeutic targeting Glycosylphosphatidylinositol (GPI) biosynthesis and cell wall biogenesis

    SBC: Prokaryotics, Inc.            Topic: NIAID

    Widespread azole resistance among Candida and Aspergillus spp. along with emerging echinocandin resistance in C. glabrata and C. auris raises the specter of untreatable multidrug resistant fungal infections, even as advances in medicine (cancer chemotherapy, organ transplant, premature infants, HIV/AIDS therapy) have increased the size of the vulnerable population. Our proposal aims to develop a n ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Next-generation nanomedicine for acute ischemic stroke

    SBC: Nanomuse, LLC            Topic: NINDS

    ABSTRACT / PROJECT SUMMARYAcute ischemic stroke is poised for a revolution. With the advent of mechanical thrombectomy in the last decade, the worst clots can be removed. While thrombectomy has improved outcomes, most treated patients still have severe deficits, in large part due to secondary injury caused by ischemia-reperfusion injury. To solve this problem, many neuroprotective drugs were trial ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. I-RED Southeast XLerator Network

    SBC: XLERATEHEALTH, LLC            Topic: 500

    Project Summary I-RED Southeast XLerator Network, powered by XLerateHealth, LLC in collaboration with the University of Kentucky as the lead academic partner institution, proposes to develop a suite of experience-based entrepreneurship education products and commercialization education tools to address the needs of academic institutions and their faculty, researchers, innovators, and graduate/unde ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Wearable Fluorescence Imaging Device for IntraoperativeIdentification of Brain Tumors

    SBC: BIOPTICS TECHNOLOGY LLC            Topic: 102

    ABSTRACT Approximately 700,000 people in the United States are diagnosed with a primary brain tumor. Of these, malignant gliomas (MGs) account for approximately 40% of all intracranial tumors, with an overall survival rate of only ~34%. Surgical resection remains the cornerstone of therapy and the extent of resection correlates with survival. Fluorescence imaging has emerged as an adjunctive techn ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Noninvasive sleep enhancement and behavior monitoring technologies for Alzheimer's model mice

    SBC: SIGNAL SOLUTIONS LLC            Topic: NIA

    The aims of this project are to develop new technologies to identify and track sleep and wake abnormalities present in mouse models of Alzheimer’s disease (AD), as well as to test a sleep enhancement technology for applications in AD animal research. Signal Solutions, LLC, has previously developed and commercialized a piezoelectric based system for noninvasive, high-throughput sleep and wake mon ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Development of compound RUEC2-118, a novel partial GABAAR positive modulator, a fast-acting treatment for general anxiety and panic disorder, to prevent opioid and benzodiazepine overdose fatalities.

    SBC: Zena Therapeutics Inc.            Topic: NIDA

    Opioid use disorder (OUD) is highly prevalent among individuals with diagnosed anxiety disorders with more than 60% of individuals with OUD reporting a lifetime anxiety disorder. Co-occurring anxiety is linked to earlier and more rapid progression into OUD, poorer treatment outcomes, and high probability of co-use of other substances, particularly benzodiazepines (BZDs). BZDs are currently the sta ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Affordable, UV-, heat- and water-resistant radiochromic film composed of diacetylenes having chromophoric groups

    SBC: JP LABORATORIES INC            Topic: 300

    Project Summary: Self-developing, instant radiochromic films based on the solid-state polymerization of diacetylenes (R-C≡C-C≡C- R’, where R and R’ are substituent groups) are used for measuring radiation therapy dose. Currently available radiochromic films, e.g., the GafChromicTM EBT films from Ashland (Bridgewater, NJ, USA), have many drawbacks such as they are very expensive, sensitive ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. A Novel Pharmacological Inhibitor of Adenylyl Cyclase Type 5 to Treat Alzheimer's Disease

    SBC: VASADE BIOSCIENCES, INC.            Topic: NIA

    Project Summary: Alzheimer’s Disease is associated with metabolic dysfunction, glucose and insulin resistance, oxidative stress, mitochondrial dysfunction, and reduced exercise capacity. Oxidative stress and mitochondrial dysfunction correlate with the development of beta-amyloid (Aβ) deposits, one of the hallmarks of AD that begin years before the onset of memory and cognitive decline. Moreove ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government